Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-16 of 16

Sort by

Sort Order Select

Journal Articles

BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality

Junko Murai, Yves Pommier

Cancer Res (2023) 83 (8): 1173–1174.

https://doi.org/10.1158/0008-5472.CAN-23-0628

Published: 14 April 2023

View article titled, BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality

Journal Articles

SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243

Yasuhisa Murai, Ukhyun Jo, Junko Murai, Lisa M. Jenkins, Shar-Yin N. Huang, Sirisha Chakka, Lu Chen, Ken Cheng, Shinsaku Fukuda, Naoko Takebe, Yves Pommier

Cancer Res (2021) 81 (11): 3067–3078.

https://doi.org/10.1158/0008-5472.CAN-20-2694

Published: 01 June 2021

View article titled, SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243

Includes: Supplementary data

Journal Articles

Abstract LB-121: The novel ATR inhibitor M4344 and CHK1 inhibitor SRA737 overcome chemoresistance in SLFN11-negative cells in combination treatment with DNA-damaging agents

Ukhyun Jo, Yasuhisa Murai, Junko Murai, Shar‐yin N Huang, Sirisha Chakka, Lu Chen, Ken Cheng, Yves Pommier

Cancer Res (2020) 80 (16_Supplement): LB-121.

https://doi.org/10.1158/1538-7445.AM2020-LB-121

Published: 15 August 2020

View article titled, Abstract LB-121: The novel ATR inhibitor M4344 and CHK1 inhibitor SRA737 overcome chemoresistance in SLFN11-negative cells in combination treatment with DNA-damaging agents

Journal Articles

Abstract 365: Indotecan (LMP400), indimitecan (LMP776) and LMP744, a new class of non-camptothecin topoisomerase I inhibitors selective for schlafen11-positive and BRCA-deficient cells that synergize with olaparib

Laetitia Marzi, Ludmila Szabova, Zoe Weaver Ohler, Shyam Sharan, Mike Beshiri, Junko Murai, Kathy Kelly, Yves Pommier

Cancer Res (2019) 79 (13_Supplement): 365.

https://doi.org/10.1158/1538-7445.AM2019-365

Published: 01 July 2019

View article titled, Abstract 365: Indotecan (LMP400), indimitecan (LMP776) and LMP744, a new class of non-camptothecin topoisomerase I inhibitors selective for schlafen11-positive and BRCA-deficient cells that synergize with olaparib

Journal Articles

Phosphatase 1 Nuclear Targeting Subunit, a Novel DNA Repair Partner of PARP1

Junko Murai, Yves Pommier

Cancer Res (2019) 79 (10): 2460–2461.

https://doi.org/10.1158/0008-5472.CAN-19-0798

Published: 15 May 2019

View article titled, Phosphatase 1 Nuclear Targeting Subunit, a Novel DNA Repair Partner of PARP1

Journal Articles

Abstract LB-244: Overcoming resistance to DNA targeted agents by epigenetic activation of Schlafen 11 (SLFN11) expression with class I histone deacetylase inhibitors

Azam Ghafoor, Sai-Wen Tang, Anish Thomas, Junko Murai, Jane B. Trepel, Susan E. Bates, Vinodh N. Rajapakse, Yves Pommier

Cancer Res (2018) 78 (13_Supplement): LB-244.

https://doi.org/10.1158/1538-7445.AM2018-LB-244

Published: 01 July 2018

View article titled, Abstract LB-244: Overcoming resistance to DNA targeted agents by epigenetic activation of Schlafen 11 (SLFN11) expression with class I histone deacetylase inhibitors

Journal Articles

Abstract 4855: Indotecan (LMP400), Imidotecan (LMP776) and LMP744: A new class of non-camptothecin TOP1 inhibitors selective for cancer cells with homologous recombination deficiencies and high SLFN11 expression

Yves Pommier, Laetitia Marzi, Zoe Waever Ohler, Ludmila Szabova, Shyam Sharan, Junko Murai, Mark Cushman

Cancer Res (2018) 78 (13_Supplement): 4855.

https://doi.org/10.1158/1538-7445.AM2018-4855

Published: 01 July 2018

View article titled, Abstract 4855: Indotecan (LMP400), Imidotecan (LMP776) and LMP744: A new class of non-camptothecin TOP1 inhibitors selective for cancer cells with homologous recombination deficiencies and high SLFN11 expression

Journal Articles

Abstract 2794: Indotecan (LMP400), imidotecan (LMP776) and LMP744: A new class of non-camptothecin Top1 inhibitors selective for homologous recombination deficient (HRD) cells

Laetitia Marzi, Keli Agama, Zoe Weaver Ohler, Ludmila Szabova, Shyam Sharan, Junko Murai, Muthana Al Abo, Yves Pommier

Cancer Res (2017) 77 (13_Supplement): 2794.

https://doi.org/10.1158/1538-7445.AM2017-2794

Published: 01 July 2017

View article titled, Abstract 2794: Indotecan (LMP400), imidotecan (LMP776) and LMP744: A new class of non-camptothecin Top1 inhibitors selective for homologous recombination deficient (HRD) cells

Journal Articles

Abstract 5875: Schlafen 11 (SLFN11) induces lethal S-phase arrest in response to DNA damage: A novel mechanism of how cancer cells are killed by DNA damaging agents

Junko Murai, Yves Pommier

Cancer Res (2017) 77 (13_Supplement): 5875.

https://doi.org/10.1158/1538-7445.AM2017-5875

Published: 01 July 2017

View article titled, Abstract 5875: Schlafen 11 (SLFN11) induces lethal S-phase arrest in response to DNA damage: A novel mechanism of how cancer cells are killed by DNA damaging agents

Journal Articles

Abstract 3736: Schlafen 11 (SLFN11) blocks RNA synthesis upon replicative damage, a novel mechanism for killing cancer cells in response to DNA damaging agents

Junko Murai, Sai-wen Tang, Yves Pommier

Cancer Res (2016) 76 (14_Supplement): 3736.

https://doi.org/10.1158/1538-7445.AM2016-3736

Published: 15 July 2016

View article titled, Abstract 3736: Schlafen 11 (SLFN11) blocks RNA synthesis upon replicative damage, a novel mechanism for killing cancer cells in response to DNA damaging agents

Journal Articles

Abstract 2849: The combination of the PARP inhibitor talazoparib (BMN 673) with the ATR inhibitor VE-821 overcomes the drug resistance of Schlafen 11-deficient cells

Junko Murai, Yves Pommier

Cancer Res (2015) 75 (15_Supplement): 2849.

https://doi.org/10.1158/1538-7445.AM2015-2849

Published: 01 August 2015

View article titled, Abstract 2849: The combination of the PARP inhibitor talazoparib (BMN 673) with the ATR inhibitor VE-821 overcomes the drug resistance of Schlafen 11-deficient cells

Journal Articles

Abstract PR4: Regulation of the Fanconi anemia pathway by a SUMO-like delivery network

Kailin Yang, George-Lucian Moldovan, Patrizia Vinciguerra, Junko Murai, Shunichi Takeda, Alan D. D'Andrea

Cancer Res (2011) 71 (18_Supplement): PR4.

https://doi.org/10.1158/1538-7445.FBCR11-PR4

Published: 28 October 2014

View article titled, Abstract PR4: Regulation of the Fanconi anemia pathway by a SUMO-like delivery network

Journal Articles

Abstract 1718: Schlafen 11 (SLFN11) is a critical determinant of cellular sensitivity to PARP inhibitors

Junko Murai, Rozenn Josse, James H. Doroshow, Yves Pommier

Cancer Res (2014) 74 (19_Supplement): 1718.

https://doi.org/10.1158/1538-7445.AM2014-1718

Published: 01 October 2014

View article titled, Abstract 1718: Schlafen 11 (SLFN11) is a critical determinant of cellular sensitivity to PARP inhibitors

Journal Articles

Abstract 3421: Differential potentiation of temozolomide and camptothecin by the PARP inhibitors olaparib and veliparib in relationship with their PARP-DNA trapping abilities, and lack of impact of PARP inhibitors on cisplatin activity.

Yves G. Pommier, Junko Murai

Cancer Res (2013) 73 (8_Supplement): 3421.

https://doi.org/10.1158/1538-7445.AM2013-3421

Published: 15 April 2013

View article titled, Abstract 3421: Differential potentiation of temozolomide and camptothecin by the PARP inhibitors olaparib and veliparib in relationship with their PARP-DNA trapping abilities, and lack of impact of PARP inhibitors on cisplatin activity.

Journal Articles

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

Junko Murai, Shar-yin N. Huang, Benu Brata Das, Amelie Renaud, Yiping Zhang, James H. Doroshow, Jiuping Ji, Shunichi Takeda, Yves Pommier

Cancer Res (2012) 72 (21): 5588–5599.

https://doi.org/10.1158/0008-5472.CAN-12-2753

Published: 31 October 2012

View article titled, Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

Includes: Supplementary data

Journal Articles

Abstract 4689: Stabilization of PARP-DNA complexes plays a critical role for the cytotoxic effects of the PARP inhibitors, veliparib and oliparib

Yves G. Pommier, Junko Murai, Shunichi Takeda

Cancer Res (2012) 72 (8_Supplement): 4689.

https://doi.org/10.1158/1538-7445.AM2012-4689

Published: 15 April 2012

View article titled, Abstract 4689: Stabilization of PARP-DNA complexes plays a critical role for the cytotoxic effects of the PARP inhibitors, veliparib and oliparib

NARROW

BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality

SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243

Abstract LB-121: The novel ATR inhibitor M4344 and CHK1 inhibitor SRA737 overcome chemoresistance in SLFN11-negative cells in combination treatment with DNA-damaging agents

Abstract 365: Indotecan (LMP400), indimitecan (LMP776) and LMP744, a new class of non-camptothecin topoisomerase I inhibitors selective for schlafen11-positive and BRCA-deficient cells that synergize with olaparib

Phosphatase 1 Nuclear Targeting Subunit, a Novel DNA Repair Partner of PARP1

Abstract LB-244: Overcoming resistance to DNA targeted agents by epigenetic activation of Schlafen 11 (SLFN11) expression with class I histone deacetylase inhibitors

Abstract 4855: Indotecan (LMP400), Imidotecan (LMP776) and LMP744: A new class of non-camptothecin TOP1 inhibitors selective for cancer cells with homologous recombination deficiencies and high SLFN11 expression

Abstract 2794: Indotecan (LMP400), imidotecan (LMP776) and LMP744: A new class of non-camptothecin Top1 inhibitors selective for homologous recombination deficient (HRD) cells

Abstract 5875: Schlafen 11 (SLFN11) induces lethal S-phase arrest in response to DNA damage: A novel mechanism of how cancer cells are killed by DNA damaging agents

Abstract 3736: Schlafen 11 (SLFN11) blocks RNA synthesis upon replicative damage, a novel mechanism for killing cancer cells in response to DNA damaging agents

Abstract 2849: The combination of the PARP inhibitor talazoparib (BMN 673) with the ATR inhibitor VE-821 overcomes the drug resistance of Schlafen 11-deficient cells

Abstract PR4: Regulation of the Fanconi anemia pathway by a SUMO-like delivery network

Abstract 1718: Schlafen 11 (SLFN11) is a critical determinant of cellular sensitivity to PARP inhibitors

Abstract 3421: Differential potentiation of temozolomide and camptothecin by the PARP inhibitors olaparib and veliparib in relationship with their PARP-DNA trapping abilities, and lack of impact of PARP inhibitors on cisplatin activity.

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

Abstract 4689: Stabilization of PARP-DNA complexes plays a critical role for the cytotoxic effects of the PARP inhibitors, veliparib and oliparib

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only